schliessen

Filtern

 

Bibliotheken

The Natural History of Clinically Complete Responders to Neoadjuvant Chemotherapy for Urothelial Carcinoma of the Bladder

To link to full-text access for this article, visit this link: http://dx.doi.org/10.1016/j.juro.2014.03.078 Byline: Alexa Meyer, Rashed Ghandour, Ari Bergman, Crystal Castaneda, Matthew Wosnitzer, Greg Hruby, Mitchell Benson, James McKiernan Abstract: We describe the clinical course of patients who... Full description

Journal Title: The Journal of Urology Sept, 2014, Vol.192(3), p.696(6)
Main Author: Meyer, A.
Other Authors: Ghandour, R. , Bergman, A. , Castaneda, C. , Wosnitzer, M. , Hruby, G. , Benson, M. , McKiernan, J.,
Format: Electronic Article Electronic Article
Language: English
Subjects:
ID: ISSN: 0022-5347
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: gale_ofa379504353
title: The Natural History of Clinically Complete Responders to Neoadjuvant Chemotherapy for Urothelial Carcinoma of the Bladder
format: Article
creator:
  • Meyer, A.
  • Ghandour, R.
  • Bergman, A.
  • Castaneda, C.
  • Wosnitzer, M.
  • Hruby, G.
  • Benson, M.
  • McKiernan, J.
subjects:
  • Adjuvant Chemotherapy
  • Antineoplastic Agents
ispartof: The Journal of Urology, Sept, 2014, Vol.192(3), p.696(6)
description: To link to full-text access for this article, visit this link: http://dx.doi.org/10.1016/j.juro.2014.03.078 Byline: Alexa Meyer, Rashed Ghandour, Ari Bergman, Crystal Castaneda, Matthew Wosnitzer, Greg Hruby, Mitchell Benson, James McKiernan Abstract: We describe the clinical course of patients who achieved cT0 status after neoadjuvant chemotherapy for muscle invasive bladder cancer. There is no established treatment paradigm for these patients. Author Affiliation: Department of Urology, Herbert Irving Cancer Center, Columbia University Medical Center, New York, New York Article History: Accepted 13 March 2014 Article Note: (footnote) Study received institutional review board approval.
language: English
source:
identifier: ISSN: 0022-5347
fulltext: fulltext
issn:
  • 0022-5347
  • 00225347
url: Link


@attributes
ID342247802
RANK0.06999999
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordid379504353
sourceidgale_ofa
recordidTN_gale_ofa379504353
sourceformatXML
sourcesystemOther
pqid1555626733
galeid379504353
display
typearticle
titleThe Natural History of Clinically Complete Responders to Neoadjuvant Chemotherapy for Urothelial Carcinoma of the Bladder
ispartofThe Journal of Urology, Sept, 2014, Vol.192(3), p.696(6)
identifierISSN: 0022-5347
subjectAdjuvant Chemotherapy ; Antineoplastic Agents
descriptionTo link to full-text access for this article, visit this link: http://dx.doi.org/10.1016/j.juro.2014.03.078 Byline: Alexa Meyer, Rashed Ghandour, Ari Bergman, Crystal Castaneda, Matthew Wosnitzer, Greg Hruby, Mitchell Benson, James McKiernan Abstract: We describe the clinical course of patients who achieved cT0 status after neoadjuvant chemotherapy for muscle invasive bladder cancer. There is no established treatment paradigm for these patients. Author Affiliation: Department of Urology, Herbert Irving Cancer Center, Columbia University Medical Center, New York, New York Article History: Accepted 13 March 2014 Article Note: (footnote) Study received institutional review board approval.
languageEnglish
source
creatorMeyer, A. ; Ghandour, R. ; Bergman, A. ; Castaneda, C. ; Wosnitzer, M. ; Hruby, G. ; Benson, M. ; McKiernan, J.;
version5
lds50peer_reviewed
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
search
scope
0gale_onefilea
1OneFile
titleThe Natural History of Clinically Complete Responders to Neoadjuvant Chemotherapy for Urothelial Carcinoma of the Bladder.
descriptionTo link to full-text access for this article, visit this link: http://dx.doi.org/10.1016/j.juro.2014.03.078 Byline: Alexa Meyer, Rashed Ghandour, Ari Bergman, Crystal Castaneda, Matthew Wosnitzer, Greg Hruby, Mitchell Benson, James McKiernan Abstract: We describe the clinical course of patients who achieved cT0 status after neoadjuvant chemotherapy for muscle invasive bladder cancer. There is no established treatment paradigm for these patients. Author Affiliation: Department of Urology, Herbert Irving Cancer Center, Columbia University Medical Center, New York, New York Article History: Accepted 13 March 2014 Article Note: (footnote) Study received institutional review board approval.
subject
0Adjuvant chemotherapy
1Antineoplastic agents
22834
3Pharmaceutical preparations
4Pharmaceutical Preparation Manufacturing
5325412
6Cancer
7Antimitotic agents
8Adjuvant treatment
general
0English
1Elsevier B.V.
2Cengage Learning, Inc.
sourceidgale_ofa
recordidgale_ofa379504353
issn
00022-5347
100225347
rsrctypearticle
creationdate2014
recordtypearticle
addtitleThe Journal of Urology
searchscopeOneFile
lsr30VSR-Enriched:[doi, eissn, pqid, pages, creator, date, galeid]
sort
titleThe Natural History of Clinically Complete Responders to Neoadjuvant Chemotherapy for Urothelial Carcinoma of the Bladder.
creationdate20140901
facets
frbrgroupid5409479038860460797
frbrtype5
languageeng
creationdate2014
topic
0Adjuvant Chemotherapy
1Antineoplastic Agents
collectionOneFile (GALE)
prefilterarticles
rsrctypearticles
jtitleJournal of Urology
toplevelpeer_reviewed
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
atitleThe Natural History of Clinically Complete Responders to Neoadjuvant Chemotherapy for Urothelial Carcinoma of the Bladder.
jtitleThe Journal of Urology
risdate20140901
volume192
issue3
spage696
issn0022-5347
formatjournal
genrearticle
ristypeJOUR
abstractTo link to full-text access for this article, visit this link: http://dx.doi.org/10.1016/j.juro.2014.03.078 Byline: Alexa Meyer, Rashed Ghandour, Ari Bergman, Crystal Castaneda, Matthew Wosnitzer, Greg Hruby, Mitchell Benson, James McKiernan Abstract: We describe the clinical course of patients who achieved cT0 status after neoadjuvant chemotherapy for muscle invasive bladder cancer. There is no established treatment paradigm for these patients. Author Affiliation: Department of Urology, Herbert Irving Cancer Center, Columbia University Medical Center, New York, New York Article History: Accepted 13 March 2014 Article Note: (footnote) Study received institutional review board approval.
pubElsevier B.V.
lad01gale_ofa
doi10.1016/j.juro.2014.03.078
pages696-701
eissn15273792
date2014-09